Literature DB >> 19738044

Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.

Bruno Ragazzon1, Laure Cazabat, Marthe Rizk-Rabin, Guillaume Assie, Lionel Groussin, Hélène Fierrard, Karine Perlemoine, Antoine Martinez, Jérôme Bertherat.   

Abstract

The cyclic AMP signaling pathway can be altered at multiple levels in endocrine tumors. Its central component is the protein kinase A (PKA). Carney complex (CNC) is a hereditary multiple neoplasia syndrome resulting from inactivating mutations of the gene encoding the PKA type I alpha regulatory subunit (PRKAR1A). Primary pigmented nodular adrenocortical disease is the most frequent endocrine tumor of CNC. Transforming growth factor beta (TGFbeta) regulates adrenal cortex physiology and signals through SMAD2/3. We used an interference approach to test the effects of PRKAR1A inactivation on PKA and TGFbeta pathways and on apoptosis in adrenocortical cells. PRKAR1A silencing stimulates PKA activity and increases transcriptional activity of a PKA reporter construct and expression of the endogenous PKA target, NR4A2, under basal conditions or after forskolin stimulation. PRKAR1A inactivation also decreased SMAD3 mRNA and protein levels via PKA, altering the cellular response to TGFbeta. SMAD3 expression was also inhibited by adrenocorticorticotropic hormone in the mouse adrenal gland and by forskolin in H295R cells. TGFbeta stimulates apoptosis in H295R cells, and this effect was counteracted by PRKAR1A inactivation. PRKAR1A silencing decreased the percentage of apoptotic cells and the cleavage of apoptosis mediators [caspase-3, poly(ADP-ribose) polymerase, and lamin A/C]. Inactivating mutations of PRKAR1A observed in adrenocortical tumors alter SMAD3, leading to resistance to TGFbeta-induced apoptosis. This cross-talk between the PKA and the TGFbeta signaling pathways reveals a new mechanism of endocrine tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738044     DOI: 10.1158/0008-5472.CAN-09-1601

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics.

Authors:  Paraskevi Salpea; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-09-05       Impact factor: 4.102

Review 2.  The cAMP pathway and the control of adrenocortical development and growth.

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Isaac Levy; Emmanouil Saloustros; Pierre Val; Constantine A Stratakis; Antoine Martinez
Journal:  Mol Cell Endocrinol       Date:  2011-10-15       Impact factor: 4.102

3.  Inactivation of the Carney complex gene 1 (PRKAR1A) alters spatiotemporal regulation of cAMP and cAMP-dependent protein kinase: a study using genetically encoded FRET-based reporters.

Authors:  Laure Cazabat; Bruno Ragazzon; Audrey Varin; Marie Potier-Cartereau; Christophe Vandier; Delphine Vezzosi; Marthe Risk-Rabin; Aziz Guellich; Julia Schittl; Patrick Lechêne; Wito Richter; Viacheslav O Nikolaev; Jin Zhang; Jérôme Bertherat; Grégoire Vandecasteele
Journal:  Hum Mol Genet       Date:  2013-10-10       Impact factor: 6.150

Review 4.  The transient cortical zone in the adrenal gland: the mystery of the adrenal X-zone.

Authors:  Chen-Che Huang; Yuan Kang
Journal:  J Endocrinol       Date:  2019-02-01       Impact factor: 4.286

5.  Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells.

Authors:  F Basso; F Rocchetti; S Rodriguez; M Nesterova; F Cormier; C A Stratakis; B Ragazzon; J Bertherat; M Rizk-Rabin
Journal:  Horm Metab Res       Date:  2014-09-30       Impact factor: 2.936

Review 6.  Transforming growth factor beta1 and aldosterone.

Authors:  Kota Matsuki; Catherine K Hathaway; Albert S Chang; Oliver Smithies; Masao Kakoki
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

7.  ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome.

Authors:  Guillaume Assié; Rossella Libé; Stéphanie Espiard; Marthe Rizk-Rabin; Anne Guimier; Windy Luscap; Olivia Barreau; Lucile Lefèvre; Mathilde Sibony; Laurence Guignat; Stéphanie Rodriguez; Karine Perlemoine; Fernande René-Corail; Franck Letourneur; Bilal Trabulsi; Alix Poussier; Nathalie Chabbert-Buffet; Françoise Borson-Chazot; Lionel Groussin; Xavier Bertagna; Constantine A Stratakis; Bruno Ragazzon; Jérôme Bertherat
Journal:  N Engl J Med       Date:  2013-11-28       Impact factor: 91.245

8.  PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.

Authors:  Zakariae Bram; Estelle Louiset; Bruno Ragazzon; Sylvie Renouf; Julien Wils; Céline Duparc; Isabelle Boutelet; Marthe Rizk-Rabin; Rossella Libé; Jacques Young; Dennis Carson; Marie-Christine Vantyghem; Eva Szarek; Antoine Martinez; Constantine A Stratakis; Jérôme Bertherat; Hervé Lefebvre
Journal:  JCI Insight       Date:  2016-09-22

9.  Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice.

Authors:  Isabelle Sahut-Barnola; Cyrille de Joussineau; Pierre Val; Sarah Lambert-Langlais; Christelle Damon; Anne-Marie Lefrançois-Martinez; Jean-Christophe Pointud; Geoffroy Marceau; Vincent Sapin; Frédérique Tissier; Bruno Ragazzon; Jérôme Bertherat; Lawrence S Kirschner; Constantine A Stratakis; Antoine Martinez
Journal:  PLoS Genet       Date:  2010-06-10       Impact factor: 5.917

Review 10.  Smad4-mediated TGF-beta signaling in tumorigenesis.

Authors:  Guan Yang; Xiao Yang
Journal:  Int J Biol Sci       Date:  2010-01-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.